Join China Hi-Tech Fair 2024, Where Innovation Meets Global Opportunity
The 26th China Hi-Tech Fair (CHTF) is set to take place on November 14-16, 2024, at the Shenzhen World Exhibition & Convention Center. As China’s leading and most influential technology event, CHTF offers an unparalleled platform for tech companies worldwide to showcase their latest innovations, engage with industry leaders, and expand their market reach.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721948434/en/
Embrace Innovation, Drive Growth
Over the past 25 years, CHTF has established itself as a beacon for technological advancement and international cooperation. With this year’s theme “Technology Leads Development, Industry Integrates Fusion,” the fair underscores the critical role of innovation in driving industrial integration and economic growth.
Concurrent Events
Alongside the exhibition, a lineup of over 150 concurrent events will explore groundbreaking ideas and foster collaboration. These include:
- The 7th China Green Economy Summit and Chinese Cities Investment Attracting Conference
- Innovative Biological Drugs and Cell Quality Progress Forum
- Molecular Diagnosis and Companion Diagnosis Summit Forum
- Antibody Drugs and New Drug R&D Innovation Forum
- Gene Sequencing Application Development Forum
- Southern University of Science and Technology Forum
- International Cross-domain Cooperation and Collaborative Development of Cross-border E-commerce Forum
- China Silicon Photonics Industry Forum
- AI Terminal, Intelligent Positioning System New Product Launch
- 2024 New Quality Productivity Summit
Unparalleled Market Access and Networking Opportunities:
- Unmatched Exposure: To attract over 500,000 attendees, including 150 domestic and international delegations from 105 countries and regions.
- Influential Audience: To engage with more than 10,000 technological projects and 5,000 exhibitors, including 800+ listed companies and 400+ CEOs and entrepreneurs from multinational corporations.
- Media Reach: To gain extensive media coverage from over 1,500 journalists representing 200 domestic and overseas media organizations, ensuring global visibility.
- Industry Leaders: To network with prominent figures such as Nobel Prize winners and top industry scholars, enhancing your brand’s credibility and influence.
CHTF is where global innovation converges, serving as a gateway to China’s booming tech market. It offers invaluable insights into market trends and fosters partnerships on a global scale, making it an unmissable event for anyone involved in the technology sector.
To register as an exhibitor, please visit here.
To register as a visitor, please visit here.
For more information, please visit www.chtf.com/english/
Follow us on Facebook/LinkedIn/X for the latest updates.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240721948434/en/
Contacts
Media Cooperation
Ms. Ocean An
ah@zhenweiexpo.com
Booth Booking
Ms. Donna Hau
hjn@zhenweiexpo.com
Visitor Enquiry
Ms. Sarah Wang
sarah@zhenweiexpo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom